CASE REPORT
A 43-year-old never-smoking woman presented with a palpable mass in the left breast. Chest radiography and computed tomography revealed a 5-cm solitary tumor in the left upper lung field (Fig. 1A , B) and multiple mediastinal lymph node enlargements in addition to the breast tumor. Contrast-enhanced brain magnetic resonance imaging revealed multiple, asymptomatic metastases in the brain (Fig. 1C ) and a skin metastasis in the scalp. Bone metastasis in the pelvis and hepatic metastasis were also observed. The resected breast sections revealed malignant neoplasia organized into either solid nests or trabeculae of tumor cells with necrotic foci and rosette-like structures ( Fig. 2A) . Tumor cells showed moderately abundant cytoplasm, pleomorphic and vesicular nuclei, and mitosis (up to 20 mitoses/2 mm 2 ). Immunohistochemical analysis showed that the tumor cells were diffusely and strongly positive for cytokeratin (CK) 7, pan-CK, and neuroendocrine markers (chromogranin, synaptophysin [ Fig. 2B ], and CD56) and negative for thyroid transcription factor-1, estrogen receptor, progesterone receptor, CK5/6, and CK20. Breast tumor specimen analysis before treatment indicated a malignant neoplasm with neuroendocrine structure that was positive for neuroendocrine markers, leading to a diagnosis of a large-cell neuroendocrine carcinoma (LCNEC) with suspected metastasis. Transbronchial biopsy of the lung tumor before treatment showed pathological and immunohistochemical findings similar to the findings for breast tumor. Tumor cells from the lung, breast, and skin were diffusely and strongly positive for anaplastic lymphoma kinase (ALK) by immunohistochemistry using rabbit monoclonal antibody (D5F3; Cell Signaling Technology, Danvers, MA) (Fig. 2C) . Fluorescence in situ hybridization analysis with break-apart probes for the ALK gene indicated the presence of an ALK rearrangement in the breast (Fig. 2D ) and lung tumors and skin metastasis. Multiplex reverse transcriptasepolymerase chain reaction revealed amplification of echinoderm microtubule-associated protein-like 4 (EML4)-ALK variant 2 (E20; A20) in the breast tumor. Clinically, the tumors were diagnosed as primary lung carcinoma with metastases, including metastasis to the breast. The patient was treated with crizotinib, the first clinically available ALK tyrosine kinase inhibitor, and the lung tumors remained stable with treatment. Six weeks later, enhanced brain magnetic resonance imaging revealed marked increase in the size of the right cerebellar and left temporal lesions (Fig. 1D) and progression of the skin metastasis, indicating both resistance of the tumors to crizotinib and progressive disease.
DISCUSSION
The case presented here is thought to be the first report of an LCNEC harboring an EML4-ALK rearrangement that also showed resistance to the ALK inhibitor crizotinib. In a subset of non-small-cell lung carcinoma, rearrangement of the EML4 and ALK genes creates the oncogenic fusion gene EML4-ALK, which encodes a chimeric protein with constitutive kinase activity that is most commonly seen in adenocarcinoma [1] [2] [3] and has been reported in two previous cases of small-cell carcinoma. 4, 5 However, neither ALK rearrangement nor amplification have been previously observed in LCNEC. 6 Wong et al. 2 reported that two of 13 cases harboring EML4-ALK rearrangements had unusual histological features representing squamous and glandular components. Therefore, some combined carcinomas comprising adenocarcinoma and nonadenocarcinoma components may show ALK arrangement. In this case, the primary lung tumor may have been a combination of LCNEC and adenocarcinoma. Clinical trials report that the ALK inhibitor crizotinib is highly effective for patients with the ALK rearrangement. 7 However, as the tumor in this case was resistant to crizotinib, ALK rearrangement may not be of practical importance in LCNEC, and neuroendocrine tumors harboring this rearrangement may be less responsive to ALK inhibitors. 
